{"id":250937,"date":"2025-02-04T00:00:00","date_gmt":"2025-02-04T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidon0226-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-5\/"},"modified":"2026-03-31T10:27:09","modified_gmt":"2026-03-31T10:27:09","slug":"epidon0226-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-epidemiology-epidemiology-dashboard","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidon0226-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-epidemiology-epidemiology-dashboard\/","title":{"rendered":"Squamous Cell Carcinoma of the Head and Neck &#8211; Epidemiology &#8211; Epidemiology Dashboard"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of <abbr data-abbreviation-entity=\"4729\" title=\"non-small-cell lung cancer\">SCCHN<\/abbr> comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed events of <abbr title=\"age-related macular degeneration\">SCCHN<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.<\/p>\n<p>SCCHN forecast data are available on Clarivate\u2019s Insights Platform in tabular format, with options to download to <abbr title=\"multiple sclerosis\">MS<\/abbr> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology&#8217;s <abbr title=\"age-related macular degeneration\">SCCHN<\/abbr> forecast answers the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of <abbr title=\"age-related macular degeneration\">SCCHN<\/abbr> and the number of new diagnoses of <abbr title=\"age-related macular degeneration\">SCCHN<\/abbr>?<\/li>\n<li>Of all people diagnosed with <abbr title=\"age-related macular degeneration\">SCCHN<\/abbr>, how many in each country across the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"age-related macular degeneration\">SCCHN<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following <abbr title=\"age-related macular degeneration\">SCCHN<\/abbr> subpopulations:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed incident cases<\/li>\n<li>Diagnosed prevalent cases<\/li>\n<li>Diagnosed metastatic and non metastatic incident cases<\/li>\n<li>Diagnosed metastatic recurrent incident cases<\/li>\n<li>Diagnosed oral cavity incident cases<\/li>\n<li>Diagnosed HPV +ve oropharynx incident cases<\/li>\n<li>Diagnosed HPV-ve oropharynx incident cases<\/li>\n<li>Diagnosed nasopharynx incident cases<\/li>\n<li>Diagnosed hypopharynx incident cases<\/li>\n<li>Diagnosed larynx incident cases<\/li>\n<li>Diagnosed other primary sites incident cases<\/li>\n<li>Diagnosed drug-treatable populations<\/li>\n<li>Diagnosed drug-treated populations<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country<\/p>\n","protected":false},"template":"","class_list":["post-250937","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-solid-tumors","biopharma-therapy-areas-squamous-cell-carcinoma-of-the-head-and-neck","biopharma-product-epidemiology","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250937","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250937\/revisions"}],"predecessor-version":[{"id":322898,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250937\/revisions\/322898"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=250937"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}